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ABSTRACT
Mast cell secretory granules are densely packed with various bioactive mediators 
including proteases of chymase, tryptase and CPA3 type. Previous studies have 
indicated that mast cells can affect the outcome of melanoma but the contribution of 
the mast cell granule proteases to such effects has not been clear. Here we addressed 
this issue by assessing mice lacking either the chymase Mcpt4, the tryptase Mcpt6 
or carboxypeptidase A3 (Cpa3), as well as mice simultaneously lacking all three 
proteases, in a model of melanoma dissemination from blood to the lung. Although 
mice with individual deficiency in the respective proteases did not differ significantly 
from wildtype mice in the extent of melanoma colonization, mice with multiple 
protease deficiency (Mcpt4/Mcpt6/Cpa3-deficient) exhibited a higher extent of 
melanoma colonization in lungs as compared to wildtype animals. This was supported 
by higher expression of melanoma-specific genes in lungs of Mcpt4/Mcpt6/CPA3-
deficient vs. wildtype mice. Cytokine profiling showed that the levels of CXCL16, a 
chemokine with effects on T cell populations and NKT cells, were significantly lower 
in lungs of Mcpt4/Mcpt6/Cpa3-deficient animals vs. controls, suggesting that multiple 
mast cell protease deficiency might affect T cell or NKT cell populations. In line with 
this, we found that the Mcpt4/Mcpt6/Cpa3-deficiency was associated with a reduction 
in cells expressing CD1d, a MHC class 1-like molecule that is crucial for presenting 
antigen to invariant NKT (iNKT) cells. Together, these findings indicate a protective 
role of mast cell-specific proteases in melanoma dissemination, and suggest that this 
effect involves a CXCL16/CD1d/NKT cell axis.
INTRODUCTION
Mast cells (MCs) are hematopoietic cells that are 
present as resident populations in virtually all tissues of the 
body, with preponderance at sites close to the exterior such 
as skin and mucosal surfaces of the lung and gut [1]. MCs are 
characterized by a large content of secretory granules, which 
are densely packed with a variety of preformed compounds, 
including histamine, serotonin, cytokines, lysosomal 
enzymes, growth factors, serglycin proteoglycans and various 
MC-restricted proteases [2]. The MC-restricted proteases 
encompass tryptases, chymases and carboxypeptidase 
A3 (CPA3), of which the former two are serine proteases 
whereas CPA3 is a Zn-containing metalloprotease [3–5]. 
These proteases are all stored in enzymatically active 
form and when MCs are activated to degranulate, e.g. by 
IgE receptor crosslinking [6] or by engagement of the 
MRGPRX2/MRGPRB2 receptor [7], large amounts of 
these proteases are released to the cell exterior and can exert 
massive proteolytic action in the tissue [3, 4].
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MCs have been implicated in a variety of 
pathological settings, most notably allergic conditions, but 
also in a range of additional pathologies such as arthritis, 
atherosclerosis, kidney inflammation and bacterial 
infection [8]. There is also substantial documentation, 
mainly from clinical studies, suggesting that MCs can 
have a role in malignant disorders, including squamous 
carcinomas, nodular sclerotic-type Hodgkin’s lymphoma, 
Waldenströms macroglobulinemia, breast cancer, prostate 
cancer and melanoma (reviewed in [9–13]).
In the case of melanoma, there is substantial 
documentation from both clinical studies and from animal 
models supporting that MCs participate in this pathology 
[14–22] (reviewed in [12]). However, there is still only 
little knowledge of the mechanism(s) by which MCs 
contribute to this malignancy. One important issue that 
has not been resolved is if the MC-restricted proteases 
contribute to melanoma pathogenesis. Clearly, since the 
MC proteases are known to cleave a variety of compounds 
of potential importance for tumor growth/dissemination 
[3, 4], there is a potential that melanoma pathology 
could be influenced by their release from MCs. Here we 
addressed this possibility by evaluating mice deficient in 
chymase (Mcpt4-/-), tryptase (Mcpt6-/-) or CPA3 (Cpa3-/-) 
in a model of melanoma colonization of the lung. 
Considering the possibility that the MC proteases may act 
in concert in the degradation of their substrates, we also 
evaluated mice with combined deficiency in Mcpt4, Mcpt6 
and Cpa3. We show that melanoma colonization of the 
lungs is enhanced in animals with simultaneous absence 
of chymase, tryptase and CPA3, suggesting a protective 
role of the MC-restricted proteases. Moreover, our data 
suggest that the enhanced melanoma colonization seen in 
Mcpt4/Mcpt6/Cpa3-deficient animals is associated with a 
defective CXCL16/CD1d/iNKT cell axis.
RESULTS
The individual absence of chymase, tryptase or 
CPA3 does not affect melanoma colonization 
of the lung
To address the role of MC chymase in the melanoma 
model we assessed mice deficient in Mcpt4 (also known 
as mouse mast cell protease 4 (mMCP4)). Mcpt4 is the 
murine functional homologue to human chymase (CMA1) 
and is the dominating enzyme with chymotrypsin-like 
activity in various tissues including skin and lung [23, 24]. 
We also assessed animals lacking Mcpt6 (also known as 
mMCP6), a tetrameric tryptase that is similar in structure 
and function to human β-tryptase [25]. In addition we 
assessed animals deficient in CPA3 [26].
To address the role of these MC proteases in 
melanoma we used a model in which B16F10 melanoma 
cells are injected intravenously (i.v.), followed by an 
assessment of melanoma colonization of the lung. 
Fourteen days after i.v. administration of the melanoma 
cells, tumor nodules were enumerated in the lungs. 
However, there was no significant difference in the extent 
of melanoma colonization of lungs when comparing 
wildtype (WT), Mcpt4-/-, Mcpt6-/- and Cpa3-/- mice (Figure 
1A). This suggests that the individual absence of Mcpt4, 
Mcpt6 or CPA3, respectively, does not affect the outcome 
in this model of melanoma colonization.
Increased melanoma colonization of lungs in 
mice with simultaneous absence of chymase, 
tryptase and CPA3
Although the individual absence of Mcpt4, Mcpt6 
or CPA3 did not affect melanoma dissemination to the 
lung, we considered the possibility that the combined 
action of these proteases can have an impact on melanoma 
colonization. This would be in agreement with previous 
studies showing that different MC proteases can act in 
concert in the degradation of selected proteins [4, 27, 
28]. To evaluate this possibility we made use of mice 
with combined deficiency in Mcpt4, Mcpt6 and CPA3 
[29]. Notably, the absence of CPA3 is known to cause 
a posttranslational defect in the storage of Mcpt5 (also 
known as mMCP5) [26], a MC-restricted protease that 
is structurally similar to CMA1 but has elastase-like 
cleavage specificity [30]. Thus, at the protein level, the 
Mcpt4/Mcpt6/Cpa3-deficient strain also lacks Mcpt5.
When assessing the Mcpt4/Mcpt6/Cpa3 multiple 
knockout (KO) strain in our model, we noted that the 
melanoma colonization of lung tissue was markedly 
higher than in WT mice (Figure 1B-1C), suggesting that 
the combined action of Mcpt4, Mcpt6, Cpa3 and Mcpt5 
is protective against melanoma dissemination to the lung. 
To substantiate this finding we also used quantitative 
real time PCR (qPCR) to measure the expression of two 
melanoma-specific genes, Dct and Gp100, in lungs of WT 
vs. multiple KO mice. As seen in Figure 1D, the increased 
melanoma colonization of lungs from multiple KO animals 
was accompanied by significantly higher levels of mRNA 
representing Dct and Gp100. Hence, these findings 
reinforce that the combined action of Mcpt4, Mcpt5, Mcpt6 
and Cpa3 protects against melanoma colonization of lungs.
A histological examination of lungs from WT vs. 
multiple KO animals confirmed extensive establishment 
of melanoma cells in lungs of animals that had 
received i.v. administration of melanoma cells (Figure 
2A). Toluidine blue staining revealed that MCs were 
present in lungs of both WT and multiple KO animals 
(Figure 2B). Notably, MCs in WT mice showed strong 
metachromatic staining, whereas MCs of multiple KO 
mice stained considerably weaker (Figure 2B). The 
latter is in agreement with the effect of Mcpt4/Mcpt6/
Cpa3-deficiency on staining properties of MCs derived 
from the peritoneum and skin [29], and suggests that the 
simultaneous absence of Mcpt4/Mcpt6/Cpa3 affects the 
ability of lung MCs to store proteoglycans (see [29]). 
MCs were seen either at a distance from the melanoma 
Oncotarget25068www.impactjournals.com/oncotarget
Figure 1: Multiple KO mice have higher tumor load in lungs compared to WT mice. 0.25 million of B16F10 cells were 
injected i.v. into WT, single KO or into multiprotease-deficient (multiple KO) mice. On day 14 post injection, the numbers of tumor nodules 
were quantified A, B. Results are presented as medians (n = 5-15). C. Representative images of lungs from WT and multiple KO mice. Note 
the higher numbers of tumor nodules in multiple KO compared to WT lungs. D. Total RNA was isolated from lungs on day14 post injection 
and subjected to qPCR analysis of the expression of melanoma-specific genes (DCT, black bars; GP100, gray bars). Expression of genes 
was evaluated relative to GAPDH and normalized to naïve mice. Results are presented as mean ± SEM; n = 8. Statistical calculations were 
performed using the Mann Whitney test.
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areas or in the vicinity of the tumors (Figure 2B). We 
also stained the tissue sections with chloroacetate 
esterase, a reagent that stains for chymotrypsin-like 
enzymes such as chymases. As seen in Figure 2C, 
the chloroacetate esterase staining was strong in WT 
tissue but substantially diminished in lungs of multiple 
KO mice. These findings suggest that Mcpt4, i.e. the 
chymase that is depleted in the multiple KO animals, 
accounts for the major part of the chymotrypsin-like 
activity in lungs of melanoma-administered WT animals. 
The residual chloroacetate esterase activity seen in 
lungs of multiple KO animals is most likely reflecting 
chymase activity attributed to Mcpt1, a chymase known 
to be expressed by lung MCs [31].
Figure 2: Histological analysis of lung tissue. On day 14 post B16F10 cell injection, lungs were paraffin imbedded, sectioned and 
stained with hematoxylin and eosin A. toluidine blue B. or for chloroacetate esterase activity C. (A) Arrows point to tumor areas. Note a 
larger tumor area in the section from multiple KO mice (right) in comparison with WT controls (left); original magnification x 200; bar 
= 50 μm. (B) Toluidine blue-positive MCs (marked by arrows) are present in lung sections from both WT (left) and multiple KO (right). 
Inserts show a higher magnification of the toluidine blue-stained MCs; note that MCs in lungs of multiple KO mice stain less intensely 
in comparison with WT MCs. (C) Chloroacetate esterase staining shows the presence of chymase-positive MCs in lung of both WT (left) 
and multiple KO (right) mice (marked by arrows): insets show larger magnifications of chloroacetate esterase-stained MCs; note that MCs 
in lungs from multiple KO mice stain less intensely with chloroacetate esterase, indicating lower content of chymase activity. Original 
magnification x 400; bars = 50 μm; bars in the inserts =10 μm.
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Absence of Mcpt4/Mcpt6/Cpa3 does not affect 
the early stages of melanoma colonization 
of lungs
The data above suggest that the simultaneous 
absence of Mcpt4/Mcpt6/Cpa3 results in increased 
melanoma colonization as manifested by the appearance of 
tumor nodules in lungs taken two weeks after melanoma 
cell administration. Next, we asked whether the absence 
of Mcpt4/Mcpt6/Cpa3 affects melanoma colonization 
at the early stages, i.e. before the appearance of visible 
tumor nodules. To address this we labeled melanoma cells 
with cell tracker orange CMRA and administered the 
labeled cells i.v.. After 9 h, single cell suspensions were 
prepared from lungs and were assessed by flow cytometry 
analysis for presence of CMRA-labeled (melanoma) cells. 
However, there was no significant effect of the combined 
absence of Mcpt4/Mcpt6/Cpa3 on the numbers of lung-
associated melanoma cells at this stage of the malignant 
process (Supplementary Figure 1). Hence, the MC 
proteases do not impact on the early stages of melanoma 
colonization of the lungs.
Expression of tumor-promoting genes in lungs of 
WT and Mcpt4/Mcpt6/Cpa3-deficient mice
In order to approach the mechanism by which the 
combined absence of Mcpt4/Mcpt6/Cpa3 could affect 
melanoma colonization, we first assessed the expression 
of various genes known to have an impact on malignant 
progression/dissemination. These analyses revealed 
that there was no difference in the expression of matrix 
metalloprotease 2 (MMP2), matrix metalloprotease 9 
(MMP9), vascular endothelial growth factor (VEGF), 
CXCL2 or fibroblast growth factor (FGF) in melanoma-
carrying WT vs. multiple KO animals (Figure 3). 
However, we noted a significant reduction in the 
expression of hepatocyte growth factor (HGF) in lungs 
from multiple KO vs. WT melanoma-carrying animals 
(Figure 3). Moreover, we noted a lower expression of 
MMP2, FGF and CXCL2 in naïve multiple KO animals 
vs. WT controls (Figure 3).
Lower levels of CXCL16 in lungs of Mcpt4/
Mcpt6/Cpa3-deficient mice
As a next approach for dissecting the mechanism 
underlying the protective role of Mcpt4/Mcpt6/Cpa3 in 
melanoma colonization, we assessed the levels of various 
cytokines and chemokines in serum of WT vs. multiple 
KO mice using an antibody-based filter array. As seen in 
Figure 4A, the majority of the compounds included in the 
array did not differ between serum from WT vs. multiple 
KO mice. However, the filter array analysis indicated that 
the levels of CXCL16, a chemokine with known ability to 
attract T cell populations and NKT cells [32], was reduced 
in serum of multiple KO animals. Similarly, the filter array 
approach indicated diminished levels of CXCL16 in lung 
tissue of multiple KO vs. WT animals (Figure 4A). To 
verify these findings with a quantitative method we used 
ELISA. Indeed, ELISA measurements confirmed that the 
levels of CXCL16 were significantly lower in lungs of 
multiple KO vs. WT animals, whereas we were not able 
to confirm the effect of combined Mcpt4/Mcpt6/Cpa3-
deficiency on the levels of CXCL16 in serum (Figure 4B). 
In line with these findings, qPCR analysis revealed that the 
expression of the CXCL16 gene was significantly lower in 
lungs of multiple KO animals that had received melanoma 
cells, as compared with naïve WT or Mcpt4/Mcpt6/Cpa3-
deficient animals (Figure 4C). In contrast, there was no 
significant difference in CXCL16 gene expression when 
comparing melanoma-carrying WT animals vs. naïve WT 
or Mcpt4/Mcpt6/Cpa3-deficient animals (Figure 4C).
CXCL16 is unique (together with CXCL1) among 
chemokines by being expressed as a transmembrane 
protein [32]. Previous studies have shown that 
CXCL16 can be shed from the cell surface to generate 
a soluble chemokine, and it has been shown that this is 
mediated by classical sheddases such as a disintegrin 
and metalloproteinase 10 (ADAM10) or ADAM17 
[32–34]. To evaluate the possibility that the differential 
levels of CXCL16 in WT vs. multiple KO animals is 
attributed to effects on the expression of sheddases, we 
compared the expression of the ADAM10 and ADAM17 
genes in lungs of WT vs. multiple KO animals. These 
analyses revealed a slight but significant decrease in 
the expression of ADAM17 in lungs from multiple KO 
vs. WT animals, whereas the expression of ADAM10 
was not affected by the absence of Mcpt4/Mcpt6/Cpa3 
(Figure 4D).
Absence of Mcpt4/Mcpt6/Cpa3 is associated with 
a decrease in CD1d-expressing cells
Next we considered the possibility that the 
altered melanoma colonization in Mcpt4/Mcpt6/
Cpa3-deficient animals might be reflected by effects 
on leukocyte recruitment into the lungs. To assess this 
we generated single cell suspensions of lungs from 
melanoma-administered WT and multiple KO animals, 
and used flow cytometry analysis to quantify various 
CD45+ leukocyte populations. The absence of Mcpt4/
Mcpt6/Cpa3 did not affect the percentage of CD3+CD4+, 
CD3+CD8+, F4/80+Cd11c+ (macrophages) or CD3-
NK1.1+ (NK) cells (Figure 5). However, we noted a 
significant reduction of the CD1d+ population in lungs 
of multiple KO mice vs. WT controls (Figure 5). In 
agreement with this finding, qPCR analysis revealed a 
significant reduction in the expression of the CD1d gene 
in multiple KO vs. WT melanoma-carrying mice (Figure 
6A). In contrast, the expression of the CD3, CD4, CD8 or 
Vα14-Jα281 (component of the T cell receptor expressed 
Oncotarget25071www.impactjournals.com/oncotarget
by iNKT cells) genes did not differ in lungs recovered 
from WT vs. multiple KO animals (Figure 6A). Hence, 
the high melanoma burden of Mcpt4/Mcpt6/Cpa3-
deficient animals is accompanied by low expression 
of CD1d, introducing the possibility that CD1d might 
have a role in regulating melanoma colonization of the 
lung. In agreement with this notion, the expression of the 
CD1d gene correlated negatively with the expression of 
melanoma-specific genes (Figure 6B).
DISCUSSION
It has been recognized for a long time that MC 
presence is a common clinical feature of malignant 
melanoma (see Introduction). In a previous study on 
this topic, the presence of MCs was correlated with poor 
prognosis [15], suggesting a detrimental role of MCs 
in this type of malignancy. A detrimental role of MCs 
in melanoma is also supported by experimental studies 
Figure 3: Expression of angiogenesis markers in lungs of naïve and melanoma-carrying mice. Total RNA was isolated from 
lungs of naïve mice (black bars) and lungs of mice taken day 14 post i.v. injection of B16F10 melanoma cells (gray bars). Total RNA was 
subjected to qPCR analysis of angiogenesis markers. Expression of genes was evaluated relative to GAPDH and normalized to naïve mice. 
Results are presented as mean ± SEM; n = 5 (black bars), n = 7-8 (gray bars). Note that mice with tumors do not show increased expression 
of angiogenesis markers compared to naïve mice and that the groups with tumors show similar expression of the markers. Statistical 
calculations were performed using the Mann Whitney test.
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Figure 4: Lower levels of CXCL16 in lungs of multiple KO mice. A. B16F10 melanoma cells were injected i.v. into either 
WT or multiple KO mice. On day14 post injection, mice were sacrificed, blood and lungs were collected (n = 3-4/genotype), and protein 
array (detecting 62 mouse proteins; setup indicated below the panel) analysis was performed on serum samples and lung homogenates as 
indicated. Squares represent CXCL16; note the lower amounts of CXCL16 in samples from multiple KO mice. B. Mouse CXCL16 ELISA 
was performed on lung homogenates (n = 9-10/genotype) and serum (n = 4-6/genotype) from naïve mice (black bars) or mice injected with 
B16F10 melanoma cells (gray bars). Results are presented as mean ± SEM. C. qPCR analysis of CXCL16 gene expression was performed 
on lung tissue from naïve (black bars, n = 4) and B16F10 melanoma-injected mice (gray bars, n = 8). Expression of genes was evaluated 
relative to GAPDH and normalized to naïve mice. Results are presented as mean ± SEM (Kruskal-Wallis test). D. qPCR analysis of 
ADAM10 and ADAM17 expression was performed on lung tissue from naïve (black bars; n = 4-5) and B16F10 melanoma-injected mice 
(gray bars; n = 8). Expression of genes was evaluated relative to GAPDH and normalized to naïve mice. Results are presented as mean ± 
SEM. Statistical calculations were performed using the Mann Whitney test.
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performed on mice lacking MCs altogether. The latter 
studies have been based on animals where the absence 
of MCs is caused either by mutations in c-kit [19, 20] or 
by MC-specific expression of Cre recombinase leading to 
diphteria toxin-mediated cellular suicide [18]. However, 
although these previous efforts support a role of MCs 
in melanoma, the mechanisms by which MCs impact 
on this type of pathology are not fully understood. One 
favored scenario though is that MCs might contribute by 
expressing pro-angiogenic factors such as VEGF [16], 
bFGF [35] and histamine [36], whereas other studies have 
suggested that MCs may account for TIM-3-mediated 
immunosuppression [37].
In contrast to the prevailing notion that MCs 
as such promote melanoma, we here report that the 
combined action of MC-restricted granule-localized 
proteases confers protection against melanoma 
colonization. Notably, our present findings are in 
agreement with a recent clinical study where it was 
shown that the presence of MC chymase and tryptase 
correlated with good prognosis [21]. Hence, the 
present findings together with previous observations 
suggest that MCs can have both tumor-promoting and 
-protective activities. As an explanation for this apparent 
dichotomy, we can envision that the tumor-suppressing 
activities of the MC proteases can balance tumor-
promoting activities of other compounds expressed by 
MCs. For example, one potential scenario is that MCs 
express tumor-promoting chemokines/growth factors, 
and that the MC proteases can regulate the levels of such 
compounds by proteolytic action. The absence of the MC 
protease system will accordingly lead to an elevation 
of factors with tumor-promoting activity; however, the 
identities of the in vivo substrates for Mcpt4/Mcpt6/
Cpa3 during the course of melanoma progression 
remain to be revealed. The suggested scenario is thus in 
analogy with previous findings demonstrating that MC 
chymase can have an anti-inflammatory role in allergic 
airway inflammation whereas MCs as such promote this 
condition [24, 38, 39]. Another example is the reported 
Figure 5: Decreased numbers of CD1d-expressing lung cells in multiple KO mice. Representative dot plots and numbers of 
A. CD45+CD3+CD4+/CD8a+ lymphocytes, B. CD45+CD11c+F4/80+ (macrophages), C. CD45+CD3-NK1.1+ (NK cells) and D. CD45+CD1d+ 
cells in lungs of melanoma-carrying WT or multiple KO mice (day 14 post melanoma administration). The bars show the mean ± SEM of 
10-11 individual mice per group pooled from two independent experiments. Mann-Whitney test; * p < 0.05.
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Figure 6: Decreased expression of CD1d in multiple KO mice. A. qPCR analysis of CD3ε, CD4, CD8b1, Vα14-Jα281 and CD1d 
expression was performed on lung tissues from B16F10 melanoma-carrying WT or multiple KO mice (n = 6-8). Expression of genes was 
evaluated relative to GAPDH and normalized to naïve mice. Results are presented as mean ± SEM. Statistical calculations were performed 
using the Mann Whitney test. B. Correlation between the expression of CD1d with expression of melanoma-specific genes: DCT and 
GP100; Nonparametric Spearman correlation.
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detrimental function of MC of chymase in immune 
complex-mediated glomerulonephritis, whereas MCs 
overall promote the pathology in this setting [40].
The proteases assessed in this study, i.e. Mcpt4, 
Mcpt6 and CPA3 (and indirectly Mcpt5), are all expressed 
by MCs of the connective tissue subtype (CTMCs), and 
our findings thus indicate the proteases expressed by 
this subclass of MCs influence melanoma colonization. 
However, lungs are also populated by mucosal type 
MCs (MMCs), which express Mcpt1 and Mcpt2. Adding 
complexity to this issue, it has been reported that mouse 
lung MCs represent a mixed phenotype, expressing both 
classical CTMC proteases but also Mcpt1 and Mcpt2 [31]. 
At present we do not know whether the MMC proteases, 
i.e., Mcpt1 or Mcpt2, influence melanoma. However, an 
assessment of Mcpt1 and Mcpt2 KO animals in melanoma 
colonization would be clearly warranted.
As regards the molecular mechanism by which the 
mast cell proteases affect melanoma dissemination, our 
findings reveal that the absence of Mcpt4/Mcpt6/Cpa3 
is associated with a decrease in ADAM17 expression. 
ADAM17 is a well-known sheddase having the ability 
to cleave off the ectodomains of a numerous cell surface 
proteins, including CXCL16 [32–34]. It is therefore 
plausible that reduced ADAM17 activity in the multiple 
KO animals could lead to less efficient shedding of 
CXCL16, thereby explaining the observed reduction in 
CXCL16 levels (Figure 4). We also noted that the absence 
of Mcpt4/Mcpt6/CPA3 was associated with alterations in 
the expression a range of other genes of potential impact 
on the melanoma colonization processes: HGF, MMP2, 
FGF, CXCL2. Possibly, the altered expression of these 
genes could thus contribute to the enhanced susceptibility 
of multiple KO animals to lung melanoma colonization.
Interestingly, it was shown in a previous study, 
utilizing a subcutaneous model of melanoma, that mice 
with defective expression of NDST2 developed larger 
metastatic lesions than did WT mice [41]. NDST2 is an 
essential enzyme in the biosynthesis of heparin in MCs 
[42, 43] and the authors suggested that the phenotype of 
the NDST2 KO was linked to the anticoagulant activity 
of heparin [41]. In our initial characterization of the 
multiple KO mice, we noted that the combined absence 
of Mcpt4/Mcpt6/CPA3 led to a reduction in the content 
of heparin in MCs [29], i.e. similar to mast cells lacking 
NDST2. Hence, it is possible that the reduction of heparin 
content in MCs derived from the multiple KO mice might 
contribute to the enhanced susceptibility to melanoma. 
However, the reduction of heparin in MCs from multiple 
KO mice is only partial (~50%) and we therefore favor the 
notion that it is the actual deficiency in proteases, rather 
than the reduction in heparin content, that is the major 
cause for the increased susceptibility of the multiple KO 
mice to melanoma. As an alternative scenario explaining 
Table 1: Primers used for qPCR analyses
Target Forward primer (5`- 3`) Reverse primer (5`- 3`)
GAPDH CTC CCA CTC TTC CAC CTT CG CCA CCA CCC TGT TGC TGT AG
DCT TCC TCC ACT CTT TTA CAG ACG ATT CGG TTG TGA CCA ATG GG
GP100 AGC ACC TGG AAC CAC ATC TA GTT CCA GAG GGC TGT GTA GT
MMP2 GCG CTT TTC TCG AAT CCA T GGG TAT CCA TCT CCA TGC TC
MMP9 CTG GAA CTC ACA CGA CAT CTT TCC ACC TTG TTC ACC TCA TTT
VEGF GGA GTC TGT GCT CTG GGA TT AAC CAA CCT CCT CAA ACC GT
CXCL2 ACA TCC CAC CCA CAC AGT GAA TCC TTC CAT GAA AGC CAT CCG
FGF CCA CAC GTC AAA CTA CAA CTC C TCG TTT CAG TGC CAC ATA CC
HGF ATC CCA AAT CGT CCT GGT ATT T CTG GCC TCT TCT ATG GCT ATT AC
CXCL16 CCT TGT CTC TTG CGT TCT TCC TCC AAA GTA CCC TGC GGT ATC
ADAM10 AGC AAC ATC TGG GGA CAA AAA GTT GGG CTT GGG ATC
ADAM17 GGT GGA CGG GAA AGA AGA AA CTA TGT GGG CTA GAA CCC TAG A
CD1d AAT CTG AAG CCC AGC AAA AGA A TTA CTC CAA CGG TGA GTC TGC
CD3ε AAC ACG TAC TTG TAC CTG AAA GCT C GAT GAT TAT GGC TAC TGC TGT CA
CD4 AGG TGA TGG GAC CTA CCT CTC GGG GCC ACC ACT TGA ACT AC
CD8b1 GAC GAA GCT GAC TGT GGT TGA GCA GGC TGA GGG TGG TAA G
Tcra-V14 GAG AGA ACT GCG TCC TTC AAT GAC TGT CAG GGA CAC AAG AC
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for the effect of NDST2 on melanoma, it is noteworthy 
that heparin is crucial for promoting the storage of MC 
proteases, including Mcpt4, Mcpt5, Mcpt6 and Cpa3 
[42]. Hence, a plausible explanation for the findings 
presented in [41] is that the increased melanoma burden 
seen in NDST2 KO animals is due to their deficiency 
in the respective NDST2-dependent MC proteases (i.e. 
Mcpt4, Mcpt5, Mcpt6, CPA3). Clearly, the latter scenario 
is in agreement with the findings presented in this study.
Our findings indicate that the levels of CXCL16 are 
significantly reduced in multiple KO animals. CXCL16 has 
previously been shown to impact on T cells, plasma cells 
and iNKT cells [32]. Hence, a plausible scenario is that the 
impaired ability of multiple KO mice to combat melanoma 
is due to effects on cell populations that are dependent on 
CXCL16. In line with this, we found that the combined 
deficiency of Mcpt4/Mcpt6/Cpa3 was associated with a 
reduction in the levels of CD1d. CD1d is expressed by a 
multitude of cell types but is specific for presentation of 
glycolipid antigens to iNKT cells [44, 45], a cell population 
previously shown to be an important player in the host’s anti-
tumor defense [46]. Our findings thus suggest that the iNKT 
cell population may be impaired in mice lacking Mcpt4/
Mcpt6/Cpa3, which could lead to impaired protection against 
melanoma dissemination. This notion was supported by our 
observed negative correlation between CD1d expression and 
melanoma burden.
Interestingly, single defects in any of the MC 
proteases were insufficient to cause increased melanoma 
progression whereas the simultaneous depletion of Mcpt4/
Mcpt6/Cpa3 at the gene level (combined with post-
translational defects in Mcpt5 storage) led to a significant 
increase in melanoma burden. One explanation for this 
might be that the individual MC proteases have distinct 
proteolytic targets during melanoma progression, but that 
the degradation of those targets alone is not sufficient 
to provide protection. Accordingly, the simultaneous 
absence of the various MC proteases could lead to the 
accumulation of several compounds whose combined 
action may enhance melanoma progression. An alternative 
scenario is that the various MC proteases act in concert 
on the same proteolytic targets, in this way resulting in 
a more rapid and extensive degradation of the respective 
substrate(s) than would be achieved by the individual 
MC proteases alone (see [4] for a discussion). Possibly, 
efficient degradation of target proteins, achieved by 
this mechanism, may be required to significantly affect 
melanoma progression.
MATERIALS AND METHODS
Mice
Wild type (WT), Mcpt4-/-, Mcpt6-/-, Cpa3-/-
 and Mcpt4/Mcpt6/Cpa3-deficient mice were all on 
C57BL/6J genetic background. The Mcpt4-/-, Mcpt6-
/-, Cpa3-/- mice as well as the Mcpt4/Mcpt6/Cpa3-
deficient mice show normal reproductive behavior and 
are fully viable. Eight- to 16-wk-old mice were used 
in all experiments. All experiments were approved by 
the Local Ethics Committee (Uppsala djurförsöksetiska 
nämnd; C 84/14).
Tumor inoculation
The B16F10 melanoma cell line was obtained from 
ATCC (CRL-6475). Tumor cells were propagated in 
DMEM supplemented with 10% FBS, 1% L-glutamine 
and 1% penicillin/streptomycin solution. Prior to 
injection into the tail vein, cells reaching approximately 
90% confluency were trypsinized, resuspended in Hanks’ 
balanced salt solution and counted using Trypan blue in 
order to adjust the cell concentration. 0.25 x 106 B16F10 
cells were injected into the tail vein. On day 14 post 
injection, mice were sacrificed and lung tissue to be used 
for flow cytometry analysis was flushed with PBS prior 
to harvesting. For histochemical analysis and evaluation 
of tumor nodules, the lung tissue was placed in 4% 
formalin (PBS buffered) solution. For quantitative real 
time RT-PCR (qPCR) analysis, protein array analysis 
or ELISA measurements, lungs were frozen on dry 
ice and stored at -80°C until use. Blood was collected 
both from B16F10-injected and naïve mice. Visible 
tumor nodules were enumerated and images were taken 
using a dissecting microscope (Leica EZ4 D; Leica 
Microsystems, Wetzlar, Germany).
When analyzing initial colonization of B16F10 cells 
in lungs, determined 9h post injection, melanoma cells 
were stained with cell tracker orange CMRA (Invitrogen, 
Carlsbad, CA) prior to the injection. For this, growing 
cells were first rinsed with serum-free medium and then 
incubated for 45 min with serum-free medium containing 
10 μM CMRA, followed by trypsinization.
RNA extraction and qPCR
Mice were euthanized; lungs were collected, 
frozen on dry ice and stored at -80°C until use. Whole 
lung tissue was homogenized in ~1.7 ml of trizol reagent 
(Invitrogen) using polytron PT1200 (Kinematica 
AG, Luzern, Switzerland). The homogenates were 
centrifuged at 12,000g for 1 min and 500 μl of the 
supernatant (corresponding to ~50 mg lung tissue) was 
used for total RNA isolation using Direct-zol RNA 
MiniPrep kit (The Epigenetics Company, Irvine, CA). 
Subsequently, total RNA concentration and purity was 
measured using a NanoDrop 1000 Spectrophotometer 
(Thermo Scientific, Wilmington, DE) and the ND-1000 
V3.7.0 program. First-strand cDNA was synthesized 
using ~100 ng RNA as template using the iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA), following the 
manufacturer’s instructions. Subsequently, qPCR was 
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performed on a 7900 HT Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA) using 100 ng 
cDNA, 250-500 nM primers (see Table 1) and SYBR 
GreenER SuperMix (Invitrogen), following the PCR 
cycling conditions recommended by the manufacturer. 
Each sample was analyzed in duplicates and qPCR data 
analysis was performed using the SDS2.3 software. 
Gene expression levels were presented relative to 
the housekeeping gene Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and relative to naïve mouse.
Histochemistry
Lung tissues fixed in 4% formalin (PBS buffered) 
were embedded in paraffin and sectioned into 6-μm 
sections. Samples were deparaffinized and stained 
either with hematoxylin and eosin, toluidine blue 
or chloroacetate esterase as previously described 
[47]. All images were generated using bright field 
using a Nikon 90i microscope (Nikon Instruments 
Europe, Amsterdam, Netherlands) and at an original 
magnification of 400x.
Protein analysis, protein array and ELISA
For protein analysis, the Mouse Cytokine 
Antibody Array C3 (cat. # AAM-CYT-3-4, RayBiotech, 
Norcross, GA), detecting 62 mouse proteins, was 
used. Whole lungs from B16F10-injected mice 
were homogenized on ice with polytron PT1200 
(Kinematica AG) in 1.9 ml of 1 x cell lysis buffer 
(cat. # AAM-CYT-3-4, RayBiotech) supplemented 
with complete protease inhibitor cocktail (Roche, 
Mannheim, Germany). Homogenates were centrifuged 
at 10,000g at 4°C for 5 min; the supernatants were 
aliquoted and stored at -80°C before use. Before 
protein array analysis, equal volumes (100 μl) of lung 
homogenates from 5 mice/genotype were mixed; the 
protein concentration of these mixed homogenates 
were determined using BCA1-KIT (Sigma, St. Louis, 
MO) and 500 μg of the samples were applied on the 
membrane. Serum samples were mixed in a similar 
manner and applied on the membrane. Membranes were 
exposed to HRS-Streptavidin and detection buffer, and 
scanned using a chemiluminiscence imaging system 
(BioRad CCD camera). Mouse CXCL16 ELISA (cat. 
# DY503, R&D Systems, Minneapolis, MN) was 
performed on lung homogenates and serum from 
naïve or B16F10-injected mice. Lung tissues were 
homogenized with polytron PT1200 in lysis buffer 
(100 mM Tris pH 8, 0.1 mM EDTA, 150 mM NaCl, 1% 
Nonidet-P40, 1mM NaH2PO4) with complete protease 
inhibitor cocktail (Roche) on ice. From each lung, 
samples corresponding to 500 μg protein were used 
for the analyses. Absorbance was determined using a 
microplate reader (Tecan Infinite 200; Tecan Austria, 
Grödig, Austria) and the Magellan V. 6.6 software.
Flow cytometry
Lungs flushed with PBS were cut into small 
pieces, transferred into gentleMACS C tubes containing 
enzyme solution from the lung dissociation kit (Miltenyi 
Biotec, Bergisch Gladbach, Germany) and digested 
using gentleMACS Octo Dissociator with Heaters 
(Miltenyi Biotec). Next, the epithelial cells and cell 
debris were removed by resuspending cells in 10 ml of 
44% Percoll (Sigma-Aldrich, St. Louis, MO) followed 
by centrifugation at 400 g, 4°C for 20 min using a 
Heraeus Megafuge 40R centrifuge (Thermo Fisher 
Scientific, Langenselbold, Germany). Lung cells were 
resuspended in 2% heat-inactivated FBS (Thermo Fisher 
Scientific, Waltham, MA) in PBS (FACS buffer), filtered 
through a 70 μm cell strainer (Corning, Corning, NY) 
and counted using Trypan blue. Two million cells/
sample were incubated with mouse BD Fc Block (BD 
Biosciences, San Jose, CA) in FACS buffer, following 
the manufacturer’s recommendation. After 10 min 
incubation at 4°C, fluorochrome-conjugated antibodies 
in FACS buffer were added and the cells were stained 
for 20 min at 4°C in darkness. Cells were rinsed twice 
with FACS buffer and analyzed on a LSR Fortessa 
flow cytometer (BD Biosciences). The following 
antibodies were used: anti-CD45-APC (30-F11), CD3-
FITC (17A2), CD1d-BV421 (1B1), CD4-PE (GK1.5), 
CD8a-PE-Cy7 (53-6.7), CD11c-BV421 (N418), NK1.1-
BV711 (PK136) and F4/80-PE (T45-2342), all from BD 
Biosciences, (Franklin Lakes, NJ). Stained cells were 
analyzed using a LSR Fortessa flow cytometer (BD 
Biosciences), and data analysis was performed using the 
FlowJo software. FMO controls with appropriate isotype 
antibodies were used to set the gates.
Statistical analysis
All analyses were performed in GraphPad Prism 
using the two-tailed unpaired Mann-Whitney test and 
Kruskal-Wallis test. Results shown are collected data 
from at least 2 independent experiments, presented as 
mean ± SEM. p values ≤0.05 were considered statistically 
significant.
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